Extrait

Background and study aims Haemophilia A is an inherited condition where there's not enough of a substance called clotting factor VIII in the blood as there should be, so the patient bleeds for longer than usual. Nuwiq is an engineered version of clotting factor VIII. The aim of this study is to find out whether treatment with Nuwiq prevents bleeding in patients with haemophilia A. Who can participate? Haemophilia A patients being treated with Nuwiq What does the study involve? The routine treatment of haemophilia A patients is documented, including all treatments with Nuwiq, any bleeding episodes, surgical procedures, and quality of life. What are the possible benefits and risks of participating? Not provided at time of registration Where is the study run from? Vivantes Klinikum (Germany) When is the study starting and how long is it expected to run for? March 2015 to March 2020 Who is funding the study? Investigator initiated and funded Who is the main contact? Jennifer Feddern

Critère d'inclusion

• Haemophilia A

Liens

• ictrp
• isrctn